Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Bayer reaches agreement to postpone more glyphosate lawsuits for settlement talks

Published 12/06/2019, 10:54 AM
Updated 12/06/2019, 10:54 AM
© Reuters. FILE PHOTO: Protests ahead of German drug and crop chemical maker Bayer's annual general meeting

FRANKFURT (Reuters) - Germany's Bayer (DE:BAYGn) has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

The company, which is facing 42,700 U.S. plaintiffs, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion.

Bayer agreed with the plaintiff to delay for about six months a case in the California Superior Court for Lake County scheduled for Jan. 15, a company spokesman said in a written statement.

A second case due to begin on Jan. 21 in the California Superior Court for Alameda County would also be postponed until a date yet to be determined.

Bayer said the postponements would provide more time for it and representatives of the plaintiffs to "engage constructively in the mediation process".

The company, which acquired the weed killer brands last year as part of a $63 billion takeover of Monsanto (NYSE:MON), has ruled out pulling the products from the U.S. market, citing regulators and extensive research which have found glyphosate to be safe.

It will early next year appeal to reverse the first three U.S. court rulings that awarded tens of millions of dollars to each plaintiff.

© Reuters. FILE PHOTO: Protests ahead of German drug and crop chemical maker Bayer's annual general meeting

Other trials initially scheduled for this year have already been postponed.

Latest comments

Any chemical burns trees root, will burn u too.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.